The global artificial intelligence in life sciences market size reached US$ 1.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.2 Billion by 2028, exhibiting a growth rate (CAGR) of 25.7% during 2023-2028. The rising prevalence of complex diseases, the increasing adoption of AI in medical imaging analysis, the integration of AI into genomics research and analysis, and the convergence of AI with emerging technologies are some of the major factors propelling the market.
|Market Size in 2022
||US$ 1.9 Billion
|Market Forecast in 2028
||US$ 8.2 Billion
|Market Growth Rate (2023-2028)
Artificial intelligence (AI) has revolutionized the field of life sciences, ushering in a new era of discovery, innovation, and healthcare advancements. AI refers to the development of computer systems that can perform tasks typically requiring human intelligence, such as learning, reasoning, and problem-solving, in the realm of life sciences. AI plays a pivotal role in various aspects of life sciences, including drug discovery, genomics, disease diagnosis, and personalized medicine. Machine learning algorithms can analyze vast datasets to identify potential drug candidates, predict protein structures, and uncover hidden patterns in biological information. This accelerates drug development and enables the design of more targeted therapies, ultimately saving time and resources.
The market is driven by the rising prevalence of complex diseases. In addition, the growing adoption of AI-powered blockchain applications is enhancing data security, interoperability, and traceability, presenting lucrative growth opportunities within the market. This convergence is expected to bring significant advancements in data management and healthcare delivery. Additionally, the increasing adoption of AI in medical imaging analysis and processing tools is reinforcing market expansion. These AI-driven tools play a pivotal role in disease diagnosis, anomaly detection, and the accurate interpretation of medical images. This heightened level of precision is increasing confidence in AI technologies within the healthcare sector. Moreover, the integration of AI into genomics research and analysis, facilitated by advanced analytical tools, is driving market growth. Researchers are increasingly utilizing AI to uncover insights into genetic factors associated with diseases and potential therapeutic targets, advancing the understanding of complex genetic interactions. The convergence of AI with emerging technologies, such as the Internet of Things (IoT) and blockchain is fostering innovation within the life sciences sector. This integration enables real-time data collection, remote patient monitoring, and the development of comprehensive healthcare solutions.
Artificial Intelligence in Life Sciences Market Trends/Drivers:
Drug Discovery and Development Acceleration
The traditional drug development process is a lengthy, costly, and often inefficient endeavor, taking over a decade to bring a new drug to market. AI transforms this landscape by expediting various stages of drug development. Machine learning algorithms analyze vast datasets, including biological and chemical information, clinical trial data, and existing drug databases, to identify potential drug candidates with unprecedented speed and accuracy. This enables researchers to pinpoint promising compounds, predict their efficacy, and optimize their properties, significantly reducing the time and cost required for drug discovery. Furthermore, AI aids in the identification of novel drug targets by analyzing complex biological interactions and pathways, uncovering potential targets that may have been previously overlooked.
Personalized Medicine and Healthcare
Traditional medical treatments often follow a one-size-fits-all approach, with medications and therapies prescribed based on broad population averages. AI harnesses the power of big data and machine learning to analyze an individual's genetic makeup, clinical history, lifestyle factors, and real-time health data to develop highly tailored treatment plans. This level of personalization ensures that patients receive treatments that are not only more effective but also less likely to cause adverse side effects. Also, AI-driven predictive models can help identify patients at higher risk of certain diseases, allowing for early intervention and preventive measures. Additionally, in oncology, AI assists in pinpointing the specific genetic mutations driving a patient's cancer, enabling oncologists to recommend targeted therapies that are more likely to be successful.
Disease Diagnosis and Biomarker Discovery
AI algorithms can analyze diverse medical data sources, including medical images, such as X-rays, MRIs, and CT scans, patient electronic health records, and genomic profiles, with exceptional accuracy and efficiency. In radiology, AI-powered image analysis can assist radiologists in detecting subtle abnormalities and flagging potential health issues, aiding in early diagnosis and treatment. Moreover, AI is instrumental in the discovery of disease biomarkers, which are crucial in identifying diseases at their earliest stages and monitoring their progression. Machine learning models can detect subtle patterns in molecular data, helping to identify specific biomarkers associated with various diseases, including cancer, Alzheimer's, and cardiovascular conditions. These biomarkers serve as early warning signs and can guide clinicians in making timely and informed decisions about patient care.
Artificial Intelligence in Life Sciences Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global artificial intelligence in life sciences market report, along with forecasts at the global, regional, and country levels for 2023-2028. Our report has categorized the market based on offering, deployment, and application.
Breakup by Offering:
Software dominates the market
The report has provided a detailed breakup and analysis of the market based on the offering. This includes software, hardware, and services. According to the report, software represented the largest segment.
Software in the context of AI encompasses a wide array of tools, platforms, and applications specifically designed to process, analyze, and interpret the immense volume of data generated in life sciences research. These software solutions utilize machine learning algorithms, natural language processing, deep learning, and other AI techniques to sift through complex biological datasets, making sense of genomics, proteomics, and clinical data. The versatility of AI software allows researchers to explore various aspects of drug discovery, disease diagnosis, and patient care with unprecedented precision and efficiency. Additionally, the scalability and adaptability of AI software make it a preferred choice for organizations operating in the life sciences domain. Researchers can customize and fine-tune AI algorithms to meet their specific research needs, whether it involves drug target identification, biomarker discovery, or patient stratification for clinical trials. This flexibility empowers scientists to adapt to evolving research objectives and swiftly respond to emerging challenges in healthcare and life sciences. Furthermore, AI software offerings are at the forefront of addressing some of the most pressing issues in the industry.
Breakup by Deployment:
Cloud-based dominate the market
The report has provided a detailed breakup and analysis of the market based on the deployment. This includes on-premises and cloud-based. According to the report, cloud-based represented the largest segment.
Cloud-based deployment offers unparalleled scalability and flexibility, which are crucial for the resource-intensive nature of AI applications in life sciences. Researchers and organizations can tap into cloud resources as needed, scaling up or down depending on the complexity and volume of data being processed. This dynamic scalability ensures that computational resources are optimally allocated, avoiding underutilization or resource bottlenecks, which can occur with on-premises solutions. Additionally, cloud-based deployment eliminates the need for significant upfront hardware and infrastructure investments. This cost-effectiveness is particularly attractive for research institutions, pharmaceutical companies, and healthcare providers looking to leverage AI without the burden of substantial capital expenditures. Cloud services provide pay-as-you-go pricing models, allowing organizations to pay only for the computing resources they consume, thus optimizing cost management. Moreover, cloud-based deployments offer the advantage of accessibility and collaboration. Researchers and scientists can access AI tools and applications from anywhere with an internet connection, facilitating collaboration across geographic boundaries and enabling real-time data sharing and analysis.
Breakup by Application:
- Drug Discovery
- Medical Diagnosis
- Clinical Trials
- Precision and Personalized Medicine
- Patient Monitoring
Drug discovery dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes drug discovery, medical diagnosis, biotechnology, clinical trials, precision and personalized medicine, and patient monitoring. According to the report, drug discovery represented the largest segment.
AI-driven drug discovery is not limited to target identification alone. AI models can predict the pharmacokinetics and toxicity profiles of potential drugs, allowing researchers to assess their safety and efficacy earlier in the development pipeline. This risk mitigation not only saves time but also reduces the likelihood of costly late-stage failures, a common challenge in the pharmaceutical industry. Additionally, AI plays a pivotal role in drug repurposing, where existing drugs are explored for new therapeutic applications. By analyzing biological data, AI algorithms can identify overlooked connections between drugs and diseases, potentially unveiling novel treatment options. This approach not only accelerates the availability of treatments for various medical conditions but also leverages existing knowledge and resources more efficiently. Furthermore, the personalized medicine revolution is closely linked to AI-driven drug discovery. As AI models analyze patients' genetic profiles, clinical histories, and real-time health data, they can identify specific genetic markers and mutations that influence drug response.
Breakup by Region:
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
North America exhibits a clear dominance, accounting for the largest artificial intelligence in life sciences market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America boasts significant investments in AI research and development. Government initiatives, private sector funding, and venture capital investments have poured into AI projects and startups, fueling innovation and technological advancements. This financial backing has accelerated the growth of AI-driven solutions, from drug discovery and genomics to healthcare analytics and personalized medicine. Moreover, North America's robust regulatory framework and intellectual property protection create a conducive environment for AI development and commercialization. Several regulatory agencies have been proactive in engaging with AI developers to establish clear guidelines and approval processes for AI-based medical devices and treatments. This regulatory clarity gives businesses confidence to invest in AI projects. Furthermore, North America's healthcare infrastructure is among the most advanced globally, making it a prime testing ground for AI applications. The region's large patient population, extensive electronic health record systems, and well-established pharmaceutical and biotech industries provide ample opportunities for AI-driven healthcare solutions to demonstrate their efficacy and impact.
Numerous companies in this market are focused on using AI to accelerate drug discovery processes. They develop AI algorithms and platforms that analyze biological data, identify potential drug candidates, predict drug interactions, and optimize drug design, all with the goal of bringing new therapies to market faster and more efficiently. Also, AI companies in the life sciences sector work on solutions for genomic analysis. They develop tools that can decipher and interpret genetic information, identify disease markers, predict disease risk, and enable personalized medicine by tailoring treatments based on an individual's genetic profile. Moreover, companies are developing AI-driven solutions that assist radiologists and pathologists in interpreting medical images such as X-rays, MRIs, and CT scans. These tools can help detect diseases and anomalies earlier and with greater accuracy. Companies are also actively engaged in predictive analytics, utilizing AI to identify disease biomarkers, predict patient outcomes, and stratify patients for clinical trials. These AI-driven insights can inform treatment decisions and improve patient care.
The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
- AiCure LLC
- Apixio Inc. (Centene Corporation)
- Atomwise Inc
- Enlitic Inc.
- International Business Machines Corporation
- Insilico Medicine Inc.
- Nuance Communications Inc.
- NuMedii Inc.
- Sensely Inc.
- Sophia Genetics SA
- In September 2022, AiCure LLC launched Site Services to Reduce Burden and Optimize Research Operations for Clinical Sites. With this offering, AiCure equips study coordinators with proactive insights into their patient populations to minimize risk across studies and optimize workflows.
- In October 2022, Multi Inc. collaborated with Enlitic Inc to Deliver AI-Powered Workflow Advantages to Radiologists. The aim of the collaboration is to bring the Enlitic Curie platform to healthcare providers to help radiology departments drive operational improvements. It is also creating more efficient processes while enhancing revenue opportunities.
- In December 2020, Atomwise Inc in partnership with FutuRx launched new AI-powered immuno-oncology biotech. This partnership introduced a new biotech incubator that is focused on uncovering treatments in immuno-oncology.
Artificial Intelligence in Life Sciences Market Report Scope:
|Base Year of the Analysis
|Scope of the Report
||Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
||Software, Hardware, Services
||Drug Discovery, Medical Diagnosis, Biotechnology, Clinical Trials, Precision and Personalized Medicine, Patient Monitoring
|| North America, Asia Pacific, Europe, Latin America, Middle East and Africa
||United States, Canada, China, Japan, India, South Korea, Australia, Indonesia, Germany, France, United Kingdom, Italy, Spain, Russia, Brazil, Mexico
||AiCure LLC, Apixio Inc. (Centene Corporation), Atomwise Inc, Enlitic Inc., International Business Machines Corporation, Insilico Medicine Inc., Nuance Communications Inc., NuMedii Inc., Sensely Inc. Sophia Genetics SA., etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Benefits for Stakeholders:
- IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the artificial intelligence in life sciences market from 2017-2028.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global artificial intelligence in life sciences market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the artificial intelligence in life sciences industry and its attractiveness.
- Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.